KRONOX vs TATVA: Stock Comparison

KRONOX vs TATVA CHIN PHARM CHEMUpdated 25 Aug 26, 4:08 PM ISTNSE & company filings

TATVA CHIN PHARM CHEM is the larger company by market capitalisation. KRONOX shows a lower P/E, a higher ROE and a higher dividend yield, while TATVA CHIN PHARM CHEM shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KRONOX leads 7; TATVA leads 6 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KRONOXTATVA

Valuation lens

What price are you paying?

Market CapContext only
₹648 Cr
₹3,756 Cr
P/E RatioKRONOX has the lower reading
19.62x
73.08x
P/B RatioTATVA has the lower reading
4.83x
4.8x
EPSTATVA has the higher reading
₹1.97
₹4.47
Book ValueContext only
₹31.3
₹334.2
Dividend YieldKRONOX has the higher reading
0.29%
0.12%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
TATVA is the larger company
₹3,756 Cr vs ₹648 Cr
P/E Ratio
KRONOX has a lower P/E
19.62x vs 73.08x
P/B Ratio
TATVA has a lower P/B
4.8x vs 4.83x
EPS
TATVA has higher earnings per share
₹4.47 vs ₹1.97
Dividend Yield
KRONOX has a higher dividend yield
0.29% vs 0.12%
Revenue Growth (TTM YoY)
TATVA has faster revenue growth
24.4% vs 0%
EPS Growth (TTM YoY)
TATVA has faster EPS growth
907.5% vs 26.7%
Qtr Sales Growth
TATVA has stronger quarterly sales growth
-12.18% vs -71.96%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKRONOXTATVA
SectorChemicalsChemicals
IndustrySpecialty ChemicalsSpecialty Chemicals

Price

MetricKRONOXTATVA
Live Price₹186.14₹1,608.7
Day Change-9.36%-3.04%
Volume10.27 L47,765
52-Week High₹223.42₹1,838.1
52-Week Low₹96₹981.5
Distance from 52W High-16.69%-12.48%

Valuation

MetricKRONOXTATVA
Market Cap₹648 Cr₹3,756 Cr
P/E Ratio19.62x73.08x
P/B Ratio4.83x4.8x
EPS₹1.97₹4.47
Book Value₹31.3₹334.2
Dividend Yield0.29%0.12%

Growth

MetricKRONOXTATVA
Revenue Growth (TTM YoY)0%24.4%
EPS Growth (TTM YoY)26.7%907.5%
Qtr Sales Growth-71.96%-12.18%
Qtr Profit Growth-73.6%-34.63%

Profitability & Leverage

MetricKRONOXTATVA
ROE23.72%5.38%
ROCE23.66%4.93%
Net Margin27.21%8.31%
Operating Margin36.85%11.83%
Debt to Equity0.01x0.15x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKRONOXTATVA
Promoter Holding74.21%72.02%
FII Holding0.04% 0.04 pp3.93% 0.11 pp
DII Holding2.07% 0.02 pp3.11% 0.12 pp
Public Holding23.67% 0.01 pp20.94% 0.23 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KRONOX and TATVA CHIN PHARM CHEM.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.